GLP-1 receptor agonists in heart failure: how far to expand use?
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This stepwise approach anchored in trial evidence strengthens confidence in the validity and applicability of the current results, reinforcing the role of GLP-1-based therapies beyond previously established benefits in the evolving management of cardiometabolic HFpEF.54,56-62”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82
Microvascular endothelial dysfunction in heart failure with preserved ejection fraction
Lam, C. S. P., & Lund, L. H. (2016) · Heart · doi:10.1136/heartjnl-2015-308852 · Cited by 81
Ferreira, J. P., Saraiva, F., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D., Packer, M., Zannad, F., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14997 · Cited by 65
Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
DRIGGIN, E., & GOYAL, P. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.01.005 · Cited by 24
Research works printed but not linked: 10
- Harrington, 2024, Worth their weight? An update on new and emerging pharmacologic agents for obesity and their potential role for persons with cardiac conditions, Curr Cardiol Rep, 26, 61, 10.1007/s11886-023-02016-z · DOI
- Kosiborod, 2024, Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials, Lancet, 10.1016/S0140-6736(24)01643-X · DOI · Paper page
- Powell-Wiley, 2018, Impact of body mass index on heart failure by race/ethnicity from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, JACC Heart Fail, 6, 233, 10.1016/j.jchf.2017.11.011 · DOI · Paper page
- Tomasoni, 2024, The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry, Eur J Heart Fail, 26, 854, 10.1002/ejhf.3112 · DOI
- Sargsyan, 2024, The effects of bariatric surgery on cardiac function: a systematic review and meta-analysis, Int J Obes (Lond), 48, 166, 10.1038/s41366-023-01412-3 · DOI · Paper page
- Anvari, 2022, Effect of bariatric surgery on natriuretic peptide levels: a systematic review and meta-analysis, Cardiol Rev, 30, 8, 10.1097/CRD.0000000000000378 · DOI
- Jalil, 2024, New mechanisms to prevent heart failure with preserved ejection fraction using glucagon-like peptide-1 receptor agonism (GLP-1 RA) in metabolic syndrome and in type 2 diabetes: a review, Int J Mol Sci, 25, 10.3390/ijms25084407 · DOI
- Michaëlsson, 2023, Myeloperoxidase inhibition reverses biomarker profiles associated with clinical outcomes in HFpEF, JACC Heart Fail, 11, 775, 10.1016/j.jchf.2023.03.002 · DOI
- Neves, 2023, Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials, J Card Fail, 29, 1107, 10.1016/j.cardfail.2023.03.017 · DOI
- Neves, 2024, Should the SELECT trial make us comfortable using GLP-1 receptor agonists in HFrEF?, J Am Coll Cardiol, 10.1016/j.jacc.2024.06.026 · DOI
Cited by
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“Fourth, only the SELECT trial included overweight participants (BMI ≥ 27 kg/m 2 ); therefore, limited data is available to assess the impact of GLP-1 RAs on HF outcomes in this subgroup [65].”
Metadata
- Authors
- Hage, C.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 404
- Issue
- 10456
- Pages
- 909-911
- ISSN
- 0140-6736
- Cited by
- 16
- References
- 5
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonists in heart failure: how far to expand use? https://app.cochat.ai/papers/10.1016/s0140-6736(24)01763-x
- The paper
- Hage, C. (2024). GLP-1 receptor agonists in heart failure: how far to expand use? The Lancet. https://doi.org/10.1016/s0140-6736(24)01763-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.